These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9631938)

  • 21. Risk factors in urinary calcium oxalate stone formation and their relation to urinary calcium oxalate supersaturation.
    Ogawa Y; Hatano T
    Int J Urol; 1996 Sep; 3(5):356-60. PubMed ID: 8886911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystallization properties in urine from calcium oxalate stone formers.
    Tiselius HG; Bek-Jensen H; Fornander AM; Nilsson MA
    J Urol; 1995 Sep; 154(3):940-6. PubMed ID: 7637098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Separate effects of urinary chondroitin sulphate and heparan sulphate on the crystallization of urinary calcium oxalate: differences between stone formers and normal control subjects.
    Shum DK; Gohel MD
    Clin Sci (Lond); 1993 Jul; 85(1):33-9. PubMed ID: 8149691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of urinary organic macromolecules on crystallization of calcium oxalate: enhancement of nucleation.
    Drach GW; Thorson S; Randolph A
    Trans Am Assoc Genitourin Surg; 1979; 71():62-6. PubMed ID: 161827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urinary saturation and risk factors for calcium oxalate stone disease based on spot and 24-hour urine specimens.
    Ogawa Y; Yonou H; Hokama S; Oda M; Morozumi M; Sugaya K
    Front Biosci; 2003 Sep; 8():a167-76. PubMed ID: 12957883
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physicochemical considerations in the development and prevention of calcium oxalate urolithiasis.
    Kok DJ; Papapoulos SE
    Bone Miner; 1993 Jan; 20(1):1-15. PubMed ID: 8453319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of calcium phosphate crystalluria: influence of pH and osmolality and invariable presence of oxalate.
    Hallson PC; Rose GA
    Br J Urol; 1989 Nov; 64(5):458-62. PubMed ID: 2611613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of magnesium on calcium oxalate urolithiasis.
    Su CJ; Shevock PN; Khan SR; Hackett RL
    J Urol; 1991 May; 145(5):1092-5. PubMed ID: 2016799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of urinary organic macromolecules on crystallization of calcium oxalate: enhancement of nucleation.
    Drach GW; Thorson S; Randolph A
    J Urol; 1980 Apr; 123(4):519-23. PubMed ID: 7365890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age, Body Mass Index, and Gender Predict 24-Hour Urine Parameters in Recurrent Idiopathic Calcium Oxalate Stone Formers.
    Otto BJ; Bozorgmehri S; Kuo J; Canales M; Bird VG; Canales B
    J Endourol; 2017 Dec; 31(12):1335-1341. PubMed ID: 29084490
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enteric hyperoxaluria secondary to small bowel resection: use of computer simulation to characterize urinary risk factors for stone formation and assess potential treatment protocols.
    Rodgers AL; Allie-Hamdulay S; Jackson GE; Sutton RA
    J Endourol; 2014 Aug; 28(8):985-94. PubMed ID: 24773381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium oxalate aggregation in whole urine, new aspects of calcium stone formation and metaphylaxis.
    Baumann JM; Affolter B; Caprez U; Henze U
    Eur Urol; 2003 Apr; 43(4):421-5. PubMed ID: 12667724
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Crystallization kinetics of calcium oxalate in fresh, minimally diluted urine: comparison of recurrent stone formers and healthy controls in a continuous mixed suspension mixed product removal crystallizer.
    Kavanagh JP; Nishio S; Garside J; Blacklock NJ
    J Urol; 1993 Mar; 149(3):614-7. PubMed ID: 8437278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The most important metabolic risk factors in recurrent urinary stone formers.
    Parvin M; Shakhssalim N; Basiri A; Miladipour AH; Golestan B; Mohammadi Torbati P; Azadvari M; Eftekhari S
    Urol J; 2011; 8(2):99-106. PubMed ID: 21656467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on crystalluria in calcium oxalate stone formers.
    Ahlstrand C; Tiselius HG; Larsson L
    Urol Res; 1984; 12(2):103-6. PubMed ID: 6539984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors for urinary calcium oxalate crystals as revealed by their specific enzymatic assay.
    Hallson PC; Rose GA
    Br J Urol; 1989 Nov; 64(5):451-7. PubMed ID: 2611612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for crystallization in the nephron: the role of renal development.
    Kok DJ; Schell-Feith EA
    J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S364-70. PubMed ID: 10541265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Estimation of 24-h excretion of some promotors and inhibitors of crystallization and degree of urine saturation with calcium oxalate in calcium urinary calculi].
    Boruczkowska A
    Pol Arch Med Wewn; 1994 Oct; 92(4):289-98. PubMed ID: 7854956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium citrate: reduced propensity for the crystallization of calcium oxalate in urine resulting from induced hypercalciuria of calcium supplementation.
    Harvey JA; Zobitz MM; Pak CY
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1223-5. PubMed ID: 4055988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.